Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | FX-909 |
| Synonyms | |
| Therapy Description |
FX-909 is a PPARG inverse agonist, which potentially decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): ND08). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| FX-909 | FX909|FX 909 | FX-909 is a PPARG inverse agonist, which potentially decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): ND08). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05929235 | Phase I | FX-909 | A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | Recruiting | USA | 0 |